{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:25:01Z","timestamp":1794324301810,"version":"4.9.0"},"reference-count":38,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Neurofibromatosis Type 2 (NF2) is a tumor syndrome characterized by an autosomal dominant pattern of inheritance. The hallmark of NF2 is the development of bilateral vestibular schwannomas (VSs), generally by 30 years of age. One of the first-line treatment options for small to medium-large VSs is radiosurgery. Although radiosurgery shows excellent results in sporadic VS, its use in NF2-related VS is still a topic of dispute. The aim of this study was to evaluate long-term tumor control, hearing preservation rates, and factors influencing outcome of optimally dosed, contemporary Gamma Knife radiosurgery (GKRS) for growing VSs in patients with NF2 and compare the findings to data obtained in patients with sporadic VS also treated by means of GKRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors performed a retrospective analysis of 47 growing VSs in 34 NF2 patients who underwent GKRS treatment performed with either the Model C or Perfexion Leksell Gamma Knife, with a median margin dose of 11 Gy. Actuarial tumor control rates were estimated using the Kaplan-Meier method. For patient- and treatment-related factors, a Cox proportional hazards model was used to identify predictors of outcome. Trigeminal, facial, and vestibulocochlear nerve function were assessed before and after treatment. NF2-related VS patients were matched 1:1 with sporadic VS patients who were treated in the same institute, and the same indications for treatment, definitions, and dosimetry were used in order to compare outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Actuarial tumor control rates in NF2 patients after 1, 3, 5, and 8 years were 98%, 89%, 87%, and 87%, respectively. Phenotype and tumor volume had significant hazard rates of 0.086 and 22.99, respectively, showing that Feiling-Gardner phenotype and a tumor volume not exceeding 6 cm\n                      <jats:sup>3<\/jats:sup>\n                      both were associated with significantly better outcome. Actuarial rates of serviceable hearing preservation after 1, 3, 5, and 7 years were 95%, 82%, 59%, and 33%, respectively. None of the patients experienced worsening of trigeminal nerve function. Facial nerve function worsened in 1 patient (2.5%). No significant differences in tumor control, hearing preservation, or complications were found in comparing the results of GKRS for NF2-related VS versus GKRS for sporadic VS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      With modern GKRS, the use of low margin doses for treating growing VSs in patients with NF2 demonstrates good long-term tumor control rates. Feiling-Gardner phenotype and tumor volume smaller than 6 cm\n                      <jats:sup>3<\/jats:sup>\n                      seem to be independently associated with prolonged progression-free survival, highlighting the clinical importance of phenotype assessment before GKRS treatment. In addition, no significant differences in tumor control rates or complications were found in the matched-control cohort analysis comparing GKRS for VS in patients with NF2 and GKRS for sporadic VS. These results show that GKRS is a valid treatment option for NF2-related VS, in addition to being a good option for sporadic VS, particularly in patients with the Feiling-Gardner phenotype and\/or tumors that are small to medium in size. Larger tumors in patients with the Wishart phenotype appear to respond poorly to radiosurgery, and other treatment modalities should therefore be considered in such cases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2016.9.jns161463","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T09:59:34Z","timestamp":1485511174000},"page":"49-59","source":"Crossref","is-referenced-by-count":39,"title":["Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas"],"prefix":"10.3171","volume":"128","author":[{"given":"Ivo J.","family":"Kruyt","sequence":"first","affiliation":[{"name":"Department of ENT, Donders Center for Neurosciences, Radboudumc, Nijmegen; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen B.","family":"Verheul","sequence":"additional","affiliation":[{"name":"Gamma Knife Center Tilburg, St. Elisabeth Hospital, Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E. J.","family":"Hanssens","sequence":"additional","affiliation":[{"name":"Gamma Knife Center Tilburg, St. Elisabeth Hospital, Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henricus P. M.","family":"Kunst","sequence":"additional","affiliation":[{"name":"Department of ENT, Donders Center for Neurosciences, Radboudumc, Nijmegen; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-jns161463","series-title":"Laryngoscope","first-page":"694","article-title":"Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2","volume":"106","author":"Abaza MM,","year":"1996","unstructured":"Abaza MM, Makariou E, Armstrong M, Lalwani AK: Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:694\u2013699, 19968656953"},{"key":"b2-jns161463","series-title":"PLoS One","first-page":"e46132","article-title":"Mechanisms of hearing loss in neurofibromatosis type 2","volume":"7","author":"Asthagiri AR,","year":"2012","unstructured":"Asthagiri AR, Vasquez RA, Butman JA, Wu T, Morgan K, Brewer CC, : Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One 7:e46132, 201223049959"},{"key":"b3-jns161463","series-title":"Br J Cancer","first-page":"998","article-title":"Neurofibromatosis 2, radiosurgery and malignant nervous system tumours","volume":"82","author":"Baser ME,","year":"2000","unstructured":"Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A: Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 82:998, 200010732777"},{"key":"b4-jns161463","series-title":"J Med Genet","first-page":"540","article-title":"The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2","volume":"42","author":"Baser ME,","year":"2005","unstructured":"Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, : The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 42:540\u2013546, 200515994874"},{"key":"b5-jns161463","series-title":"Cancer","first-page":"8","article-title":"Sarcoma arising in irradiated bone: report of eleven cases. 1948.","volume":"82","author":"Cahan WG,","year":"1998","unstructured":"Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL: Sarcoma arising in irradiated bone: report of eleven cases. 1948.. Cancer 82:8\u201334, 19989428476"},{"key":"b6-jns161463","series-title":"Orphanet J Rare Dis","first-page":"16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans DG:","year":"2009","unstructured":"Evans DG: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16, 200919545378"},{"key":"b7-jns161463","series-title":"Q J Med","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans DG,","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, : A clinical study of type 2 neurofibromatosis. Q J Med 84:603\u2013618, 19921484939"},{"key":"b8-jns161463","series-title":"J Med Genet","first-page":"450","article-title":"Genotype\/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations","volume":"35","author":"Evans DG,","year":"1998","unstructured":"Evans DG, Trueman L, Wallace A, Collins S, Strachan T: Genotype\/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 35:450\u2013455, 19989643284"},{"key":"b9-jns161463","series-title":"Otol Neurotol","first-page":"835","article-title":"Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium","volume":"30","author":"Fisher LM,","year":"2009","unstructured":"Fisher LM, Doherty JK, Lev MH, Slattery WH: Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol 30:835\u2013841, 200919704365"},{"key":"b10-jns161463","series-title":"Ann Otol Rhinol Laryngol","first-page":"55","article-title":"Hearing preservation in unilateral acoustic neuroma surgery","volume":"97","author":"Gardner G,","year":"1988","unstructured":"Gardner G, Robertson JH: Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 97:55\u201366, 19883277525"},{"key":"b11-jns161463","series-title":"Acta Otolaryngol","first-page":"51","article-title":"Hearing deterioration in patients with a non-growing vestibular schwannoma","volume":"123","author":"Graamans K,","year":"2003","unstructured":"Graamans K, Van Dijk JE, Janssen LW: Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta Otolaryngol 123:51\u201354, 200312625573"},{"key":"b12-jns161463","series-title":"Otolaryngol Head Neck Surg","first-page":"146","article-title":"Facial nerve grading system","volume":"93","author":"House JW,","year":"1985","unstructured":"House JW, Brackmann DE: Facial nerve grading system. Otolaryngol Head Neck Surg 93:146\u2013147, 19853921901"},{"key":"b13-jns161463","series-title":"Arch Otolaryngol Head Neck Surg","first-page":"424","article-title":"The development of the Dizziness Handicap Inventory","volume":"116","author":"Jacobson GP,","year":"1990","unstructured":"Jacobson GP, Newman CW: The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 116:424\u2013427, 19902317323"},{"key":"b14-jns161463","series-title":"J Neurosurg","first-page":"1619","article-title":"Gamma Knife radiosurgery for vestibular schwannomas: evaluation of tumor control and its predictors in a large patient cohort in The Netherlands","volume":"124","author":"Klijn S,","year":"2016","unstructured":"Klijn S, Verheul JB, Beute GN, Leenstra S, Mulder JJ, Kunst HP, : Gamma Knife radiosurgery for vestibular schwannomas: evaluation of tumor control and its predictors in a large patient cohort in The Netherlands. J Neurosurg 124:1619\u20131626, 2016"},{"key":"b15-jns161463","series-title":"N Engl J Med","first-page":"1426","article-title":"Long-term outcomes after radiosurgery for acoustic neuromas","volume":"339","author":"Kondziolka D,","year":"1998","unstructured":"Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC: Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 339:1426\u20131433, 19989811917"},{"issue":"Suppl","key":"b16-jns161463","series-title":"J Neurosurg","first-page":"195","article-title":"Radiosurgery of vestibular schwannomas: summary of experience in 829 cases","volume":"102","author":"Lunsford LD,","year":"2005","unstructured":"Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D: Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg 102:Suppl195\u2013199, 200515662809"},{"key":"b17-jns161463","series-title":"Neurosurgery","first-page":"292","article-title":"Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes","volume":"74","author":"Mallory GW,","year":"2014","unstructured":"Mallory GW, Pollock BE, Foote RL, Carlson ML, Driscoll CL, Link MJ: Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes. Neurosurgery 74:292\u2013301, 201424335819"},{"key":"b18-jns161463","series-title":"B-ENT","first-page":"29","article-title":"Hearing preservation and tumour control after radiosurgery for NF2-related vestibular schwannomas","volume":"9","author":"Massager N,","year":"2013","unstructured":"Massager N, Delbrouck C, Masudi J, De Smedt F, Devriendt D: Hearing preservation and tumour control after radiosurgery for NF2-related vestibular schwannomas. B-ENT 9:29\u201336, 201323641588"},{"key":"b19-jns161463","series-title":"Otol Neurotol","first-page":"150","article-title":"Hearing changes after diagnosis in neurofibromatosis type 2","volume":"25","author":"Masuda A,","year":"2004","unstructured":"Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH: Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 25:150\u2013154, 200415021775"},{"key":"b20-jns161463","series-title":"Neurosurgery","first-page":"460","article-title":"Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates","volume":"60","author":"Mathieu D,","year":"2007","unstructured":"Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, : Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460\u2013470, 200717327790"},{"key":"b21-jns161463","series-title":"Int J Radiat Oncol Biol Phys","first-page":"985","article-title":"Radiotherapy for vestibular schwannomas: a critical review","volume":"79","author":"Murphy ES,","year":"2011","unstructured":"Murphy ES, Suh JH: Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys 79:985\u2013997, 201121353158"},{"key":"b22-jns161463","series-title":"Arch Otolaryngol Head Neck Surg","first-page":"143","article-title":"Development of the Tinnitus Handicap Inventory","volume":"122","author":"Newman CW,","year":"1996","unstructured":"Newman CW, Jacobson GP, Spitzer JB: Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg 122:143\u2013148, 19968630207"},{"key":"b23-jns161463","series-title":"Neurosurgery","first-page":"1299","article-title":"Reduced-dose radiosurgery for vestibular schwannomas","volume":"49","author":"Petit JH,","year":"2001","unstructured":"Petit JH, Hudes RS, Chen TT, Eisenberg HM, Simard JM, Chin LS: Reduced-dose radiosurgery for vestibular schwannomas. Neurosurgery 49:1299\u20131307, 200111846928"},{"key":"b24-jns161463","series-title":"Cancer","first-page":"390","article-title":"Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation","volume":"115","author":"Phi JH,","year":"2009","unstructured":"Phi JH, Kim DG, Chung HT, Lee J, Paek SH, Jung HW: Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 115:390\u2013398, 200919109818"},{"issue":"Suppl","key":"b25-jns161463","series-title":"J Neurosurg","first-page":"745","article-title":"Gamma surgery for vestibular schwannoma","volume":"119","author":"Prasad D,","year":"2013","unstructured":"Prasad D, Steiner M, Steiner L: Gamma surgery for vestibular schwannoma. J Neurosurg 119:Suppl745\u2013759, 2013"},{"key":"b26-jns161463","series-title":"Prog Neurol Surg","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000100100","article-title":"Modern management of vestibular schwannomas","volume":"20","author":"R\u00e9gis J,","year":"2007","unstructured":"R\u00e9gis J, Roche PH, Delsanti C, Thomassin JM, Ouaknine M, Gabert K, : Modern management of vestibular schwannomas. Prog Neurol Surg 20:129\u2013141, 200717317981"},{"key":"b27-jns161463","series-title":"Nature","first-page":"515","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2","volume":"363","author":"Rouleau GA,","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, : Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515\u2013521, 1993"},{"key":"b28-jns161463","series-title":"Neurosurgery","first-page":"860","article-title":"Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes","volume":"60","author":"Rowe J,","year":"2007","unstructured":"Rowe J, Grainger A, Walton L, Radatz M, Kemeny A: Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes. Neurosurgery 60:860\u2013864, 200717460521"},{"key":"b29-jns161463","series-title":"Prog Neurol Surg","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000156907","article-title":"Radiosurgery for type II neurofibromatosis","volume":"21","author":"Rowe J,","year":"2008","unstructured":"Rowe J, Radatz M, Kemeny A: Radiosurgery for type II neurofibromatosis. Prog Neurol Surg 21:176\u2013182, 200818810217"},{"key":"b30-jns161463","series-title":"J Neurol Neurosurg Psychiatry","first-page":"1288","article-title":"Clinical experience with Gamma Knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis","volume":"74","author":"Rowe JG,","year":"2003","unstructured":"Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA: Clinical experience with Gamma Knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74:1288\u20131293, 200312933938"},{"key":"b31-jns161463","series-title":"Neurosurgery","first-page":"684","article-title":"Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve\u2014preservation and restitution of function","volume":"40","author":"Samii M,","year":"1997","unstructured":"Samii M, Matthies C: Management of 1000 vestibular schwannomas (acoustic neuromas): the facial nerve\u2014preservation and restitution of function. Neurosurgery 40:684\u2013695, 19979092841"},{"issue":"Suppl","key":"b32-jns161463","series-title":"J Neurosurg","first-page":"160","article-title":"Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate","volume":"121","author":"Seferis C,","year":"2014","unstructured":"Seferis C, Torrens M, Paraskevopoulou C, Psichidis G: Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg 121:Suppl160\u2013166, 201425434949"},{"key":"b33-jns161463","series-title":"Nature","first-page":"644","article-title":"Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma","volume":"322","author":"Seizinger BR,","year":"1986","unstructured":"Seizinger BR, Martuza RL, Gusella JF: Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322:644\u2013647, 19863092103"},{"key":"b34-jns161463","series-title":"Clin Genet","first-page":"163","article-title":"Further genotype\u2013phenotype correlations in neurofibromatosis 2","volume":"77","author":"Selvanathan SK,","year":"2010","unstructured":"Selvanathan SK, Shenton A, Ferner R, Wallace AJ, Huson SM, Ramsden RT, : Further genotype\u2013phenotype correlations in neurofibromatosis 2. Clin Genet 77:163\u2013170, 201019968670"},{"key":"b35-jns161463","series-title":"J Neurooncol","first-page":"265","article-title":"Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2","volume":"98","author":"Sharma MS,","year":"2010","unstructured":"Sharma MS, Singh R, Kale SS, Agrawal D, Sharma BS, Mahapatra AK: Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J Neurooncol 98:265\u2013270, 201020405305"},{"issue":"Suppl","key":"b36-jns161463","series-title":"J Neurosurg","first-page":"143","article-title":"Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2","volume":"121","author":"Sun S,","year":"2014","unstructured":"Sun S, Liu A: Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2. J Neurosurg 121:Suppl143\u2013149, 201425434947"},{"key":"b37-jns161463","series-title":"Laryngoscope","first-page":"1076","article-title":"Gamma Knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose","volume":"119","author":"Timmer FC,","year":"2009","unstructured":"Timmer FC, Hanssens PE, van Haren AE, Mulder JJ, Cremers CW, Beynon AJ, : Gamma Knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose. Laryngoscope 119:1076\u20131081, 2009"},{"key":"b38-jns161463","series-title":"Cell","first-page":"791","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter JA,","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, : A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791\u2013800, 19938453669"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/128\/1\/article-p49.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/128\/1\/article-p49.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/128\/1\/article-p49.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:35:45Z","timestamp":1743377745000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/128\/1\/article-p49.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3171\/2016.9.jns161463","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}